<DOC>
	<DOCNO>NCT00070252</DOCNO>
	<brief_summary>Phase I/II trial study effectiveness neoadjuvant tipifarnib combine docetaxel capecitabine treat patient locally advance metastatic solid tumor stage IIIA stage IIIB breast cancer . Tipifarnib may stop growth tumor cell block enzymes necessary cancer cell growth . Drugs use chemotherapy , docetaxel capecitabine , use different way stop tumor cell divide stop grow die . Combining tipifarnib docetaxel capecitabine may kill tumor cell .</brief_summary>
	<brief_title>Neoadjuvant Tipifarnib , Docetaxel , Capecitabine Treating Patients With Locally Advanced Metastatic Solid Tumors Stage IIIA Stage IIIB Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose recommend dose capecitabine combination docetaxel tipifarnib patient locally advance metastatic solid tumor . ( Phase Ib ) II . Determine complete pathological clinical response rate patient stage IIIA IIIB breast cancer treat regimen . ( Phase II ) SECONDARY OBJECTIVES : I . Determine toxicity regimen patient . II . Determine disease-free overall survival patient treat regimen . OUTLINE : This multicenter , dose-escalation study capecitabine . Patients phase II stratify accord type breast cancer ( inflammatory v noninflammatory ) . Phase Ib : Patients receive oral tipifarnib twice daily oral capecitabine twice daily day 1-14 docetaxel IV 30-60 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Phase II : Patients receive oral tipifarnib twice daily 6 day . Beginning least 48 hour completion initial dose tipifarnib , patient receive treatment phase Ib 6 course MTD capecitabine . Patients phase Ib follow 3 month . Patients phase II follow every 4 month 5 year . PROJECTED ACCRUAL : A total 24-53 patient ( 9-18 phase Ib 15-35 phase II ) accrue study within 14-35 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor Locally advance metastatic No known standard therapy potentially curative definitely capable extend life expectancy No history metastatic brain disease within past 6 month Treated metastatic brain disease allow provided disease stable 6 month require concurrent steroid antiseizure medication Histologically confirm breast cancer Stage IIIA stage IIIB , include ipsilateral palpable supraclavicular lymph node ( ) without distant metastasis Invasive disease confirm 1 following* : Incisional biopsy Punch biopsy ( applicable clinical T4b tumor ) Core needle ( cut needle ) biopsies No distant metastatic disease Hormone receptor status : Not specify Male female Performance status ECOG 01 Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10.0 g/dL Bilirubin great upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN AST great 2.5 time ULN Creatinine great 1.25 time ULN Creatinine clearance least 50 mL/min No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require antibiotic No diabetes No symptomatic neurologic condition No uncontrolled serious medical condition No malignancy within past 3 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No history hypersensitivity intravenous paclitaxel medication contain Cremophor EL polysorbate 80 carrier ( phase Ib ) Phase Ib : More 4 week since prior immunotherapy More 4 week since prior biologic therapy No concurrent immunotherapy Phase Ib II : No concurrent prophylactic filgrastim ( GCSF ) Phase Ib : More 1 year since prior adjuvant docetaxel metastatic relapse More 4 week since prior chemotherapy recover No prior capecitabine AND docetaxel ( combination single agent ) Prior capecitabine OR docetaxel allow No concurrent chemotherapy Phase II : No prior cytotoxic chemotherapy breast cancer Phase Ib : More 3 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Phase II : No prior radiotherapy breast cancer Phase Ib : More 4 week since prior major surgery Phase II : No prior surgery ( core incisional biopsy diagnostic purpose ) breast cancer Phase Ib : No ancillary investigational therapy Phase Ib II : No concurrent sorivudine brivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>